LDC has made an £18 million minority investment in TMC Pharma Services (TMC), a global pharmaceutical development organisation that specialises in innovative treatments for rare diseases and oncology.
The mid-market private equity firm is backing the existing TMC management team, led by Co-Founder and CEO Julie Matthews and COO Carol Woodward. Its minority investment will help TMC to further expand into the US and Asia markets. The business also plans to double the number of full-time employees it has over the next five years and open new offices in key international markets.
TMC has successfully supported over 150 Orphan Drug Designations in the past 10 years; in the USA, EU, Japan and Australia. The business provides a full range of expert pharma and biotech support services, from pre-clinical to post-marketing, for human medicines and devices.
TMC’s senior team, based in the UK, is supported by a worldwide network of over 900 contracted Associates
